ArticleRNA & disease (Houston, Tex.)
Fast-forward generation of effective artificial small RNAs for enhanced antiviral defense in plants.
Article in RNA & disease (Houston, Tex.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- syn-tasiRnas targeting the coat protein of potato virus Y confer antiviral resistance inPlant signaling & behavior · 2024Article
- Strategies for Engineering Virus Resistance in Potato.Plants (Basel, Switzerland) · 2023Review
- SilencingPotato research · 2023Article
- Targeting of genomic and negative-sense strands of viral RNA contributes to antiviral resistance mediated by artificial miRNAs and promotes the emergence of complex viral populations.Molecular plant pathology · 2022Article
- Artificial microRNA guide strand selection from duplexes with no mismatches shows a purine-rich preference for virus- and non-virus-based expression vectors in plants.Plant biotechnology journal · 2022Article
- Genomic diversity of Areca Palm Velarivirus 1 (APV1) in Areca palm (Areca catechu) plantations in Hainan, China.BMC genomics · 2021Article
- Detection of Plant Viruses and Disease Management: Relevance of Genetic Diversity and Evolution.Frontiers in plant science · 2020Review
- Innovative RNAi Strategies and Tactics to Tackle Plum Pox Virus (PPV) Genome inPlants (Basel, Switzerland) · 2019Article
- Multi-targeting of viral RNAs with synthetic trans-acting small interfering RNAs enhances plant antiviral resistance.The Plant journal : for cell and molecular biology · 2019Article
- Engineering Disease-Resistant Cassava.Cold Spring Harbor perspectives in biology · 2019Review
- Artificial microRNAs and synthetic trans-acting small interfering RNAs interfere with viroid infection.Molecular plant pathology · 2017Article
- Artificial MicroRNA-Based Specific Gene Silencing of Grain Hardness Genes in Polyploid Cereals Appeared to Be Not Stable Over Transgenic Plant Generations.Frontiers in plant science · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Artificial small RNAs (sRNAs) are short ≈21-nt non-coding RNAs engineered to inactivate sequence complementary RNAs. In plants, they have been extensively used to silence cellular transcripts in gene function analyses and to target invading RNA viruses to induce resistance. Current artificial sRNA-based antiviral resistance in plants is mainly limited to a single virus, and is jeopardized by the emergence of mutations in the artificial sRNA target site or by the presence of co-infecting viruses. Hence, there is a need to further develop the artificial sRNA approach to generate more broad and durable antiviral resistance in plants. A recently developed toolbox allows for the time and cost-effective large-scale production of artificial sRNA constructs in plants. The toolbox includes the P-SAMS web tool for the automated design of artificial sRNAs, and a new generation of artificial microRNA and synthetic
Indexed as
Identifiers
26925463PMC4768481What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.